Amphastar Pharmaceuticals AMPH Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's gain/loss on asset sales?
- Amphastar Pharmaceuticals (AMPH) reported gain/loss on asset sales of -$4K in Q1 2026.
- How has Amphastar Pharmaceuticals's gain/loss on asset sales changed year-over-year?
- Amphastar Pharmaceuticals's gain/loss on asset sales decreased by 100.0% year-over-year, from -$2K to -$4K.
- What is the long-term trend for Amphastar Pharmaceuticals's gain/loss on asset sales?
- Over 3 years (2021 to 2025), Amphastar Pharmaceuticals's gain/loss on asset sales has grown at a -51.8% compound annual growth rate (CAGR), from -$348K to -$39K.
- What does gain/loss on asset sales mean?
- Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.